Another Vital Step Towards Making Respiratory Care More Accessible and Effective
Widely recognized for its inroads in respiratory healthcare, Sanrai Med India Pvt Ltd announced a significant alliance with Swedish Ventilator and sleep devices' manufacturer, Breas on 26th Sep 2016 to 1st Oct 2016. As a result of this partnership, Sanrai intends to simplify sleep therapy, home and hospital ventilation tremendously.
Breas Medical, a company founded in 1991 was the first to produce reliable ventilation products suitable for catering to even the most complicated patient requirements. With Sanrai, they wish to extend their excellence to the Indian healthcare ecosystem like never before. Commenting on the event, Mr. Richard Fischbaeck, General Manager Distributor Regions EMEA, Breas Medical said that they couldn’t ask for a better partner than Sanrai for broadening their reach in India. Mr. Carl Van Loey Global Marketing and Clinical Applications Manager for Breas also expressed his enthusiasm about this alliance. He said that Indian patients and healthcare professionals will benefit immensely through the simplicity, effectiveness and clinical excellence of all the Breas products.
Sanrai and Breas will be bringing an extensive range of iSleep range of products which are designed to treat patients suffering from a serious disorder called "sleep apnea". Not only that, they are launching a highly functional range of ventilators, Vivo, meant for both home and hospital use. Breas ventilators are already being used in many major hospitals of India and several other countries, and Breas partnership with Sanrai, they plan to make it even more accessible. Breas also conducted detailed training on their products and technologies to ensure that Sanrai's representatives are able to educate the patients sufficiently. Enabling the patient to take the right facilitating right decision for their treatment. Brig. Pall S Sandhu, the Chairman, Sanrai Group added, "The biggest objective of this union is to keep making life easier for Indian patients by giving them international standard treatment at affordable costs.".